Announced
Financials
Sources
Tags
United Kingdom
Pharmaceuticals
specialty pharma
cannabis company
medical cannabis
Pending
Private
Majority
Single Bidder
Cross Border
Acquisition
Friendly
Synopsis
Curaleaf, a US provider of consumer products in cannabis, agreed to acquire EMMAC Life Sciences, the vertically integrated independent cannabis company in Europe, for $286m. "The consumer and political liberalization trends around cannabis that are sweeping the US are also increasingly taking hold in Europe. Curaleaf will seek to leverage our branded cannabis consumer packaged goods strategy across Europe, a market which provides for cross-border cannabis distribution. The European cannabis market has the potential to exceed the US cannabis market over the long-term and will help fuel our growth for years to come," Boris Jordan, Curaleaf Executive Chairman.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.